3/10
08:35 am
rnac
Cartesian Therapeutics (RNAC) had its "outperform" rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
Medium
Report
Cartesian Therapeutics (RNAC) had its "outperform" rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
3/9
06:05 pm
rnac
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by BTIG Research.
Medium
Report
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by BTIG Research.
3/9
12:42 pm
rnac
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.
Medium
Report
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.
3/9
11:00 am
rnac
Cartesian Therapeutics (RNAC) was upgraded by Cantor Fitzgerald from "neutral" to "overweight". They now have a $16.00 price target on the stock.
High
Report
Cartesian Therapeutics (RNAC) was upgraded by Cantor Fitzgerald from "neutral" to "overweight". They now have a $16.00 price target on the stock.
3/9
07:03 am
rnac
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/9
07:00 am
rnac
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
High
Report
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
2/23
07:02 am
rnac
Cartesian Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Cartesian Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/23
07:00 am
rnac
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
2/3
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Low
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
1/9
10:58 am
rnac
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.
Medium
Report
Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.
1/9
08:13 am
rnac
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]
1/9
08:04 am
rnac
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Medium
Report
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
1/6
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
12/18
04:36 pm
rnac
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]
Low
Report
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]
12/18
04:05 pm
rnac
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Low
Report
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors